Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as an Elite provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.

Marc Ernstoff is an Oncologist in Frederick, Maryland. Dr. Ernstoff is rated as an Elite provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), Neuroendocrine Tumor, and Urothelial Cancer.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Elite provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Dr. Janis Taube is a professor of dermatology and pathology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. Her area of clinical expertise is dermatopathology. Dr. Taube serves as the Director of the Division of Dermatopathology and as the Assistant Director of the Dermatoimmunology Laboratory at the School of Medicine. Dr. Taube received her undergraduate degree in engineering from Duke University. She earned her M.D. from Tulane University and her M.Sc. in molecular medicine from University College London. She completed her residency in pathology at Johns Hopkins where she also served as the chief resident, before undertaking a dermatopathology fellowship at Stanford University. In 2009, Dr. Taube returned to Johns Hopkins for her certification in the Melanoma Clinic. She is one of the lead scientific researchers in the Department of Dermatology at Johns Hopkins. She has written over 180 peer-reviewed publications, and her research has been cited over 70,000 times. In addition to running her own research laboratory, she serves as the co-Director of the Mark Foundation Center for Advanced Genomics and Imaging and also as the co-Director of the Tumor Microenvironment Core Laboratory for the Bloomberg~Kimmel Institute for Cancer Immunotherapy. Dr. Taube is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Basal Cell Skin Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Pancreaticoduodenectomy.

Francesco Marincola is a Surgical Oncologist in Bethesda, Maryland. Dr. Marincola is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Breast Cancer, Colorectal Cancer, and Gliomatosis Cerebri.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Dr. Topalian is a physician-scientist whose studies of anti-tumor immunity have been foundational in developing cancer immunotherapy. She has published over 160 original research articles and reviews in this area and is one of the most highly cited researchers in the biomedical field. She received her medical and scientific training at Tufts University School of Medicine, Thomas Jefferson University Hospital, Children’s Hospital of Philadelphia and the National Cancer Institute. She joined the Johns Hopkins Kimmel Cancer Center in 2006 as the inaugural director of its Melanoma Program. Dr. Topalian is credited with advancing the clinical development of anti-PD-1 immunotherapy, and her work is widely recognized. She was named one of Nature’s 10 in 2014, and received the Karnofsky Award from ASCO in 2015, the Taubman Prize in 2016, the NCI’s Rosalind E. Franklin Award in 2018, the American Academy of Dermatology’s Gruber Memorial Cancer Research Award in 2020, and the Award for Distinguished Research in the Biomedical Sciences from the Association of American Medical Colleges in 2021 for landmark discoveries in cancer immunotherapy. Dr. Topalian was elected to the National Academy of Medicine in 2017, and to the American Association for Cancer Research Academy in 2022. Her work has opened new avenues of scientific investigation and established immunotherapy as a pillar of oncology. Dr. Topalian is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Merkel Cell Carcinoma, Melanoma, Neuroendocrine Tumor, and Anal Cancer.

Petr Hausner is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Hausner is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Pseudomyxoma Peritonei, Colorectal Cancer, Familial Colorectal Cancer, and Anal Cancer. Dr. Hausner is currently accepting new patients.

Md Siddiqui is a Hematologist Oncology specialist and a Hematologist in Salisbury, Maryland. Dr. Siddiqui is rated as an Experienced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Pulmonary Embolism, Inflammatory Breast Cancer, Angiosarcoma, and Childhood Iron Deficiency Anemia. Dr. Siddiqui is currently accepting new patients.

Dr. Julie Lange is an assistant professor of surgery, dermatology and oncology at the Johns Hopkins University School of Medicine. Dr. Lange was one of the original members of the Johns Hopkins melanoma group when it was first formed in 1995 and now serves as a clinical co-director of the Melanoma Program. Dr. Lange introduced the sentinel node technique to Johns Hopkins for both melanoma and breast cancer in the 1990s and has extensive experience with this technique. Dr. Lange is a graduate of the Vanderbilt University School of Medicine and completed her general surgery training at Yale-New Haven Hospital. She completed a fellowship in surgical oncology and immunotherapy at the Surgery Branch of the National Cancer Institute as well. Dr. Lange joined the faculty of the Department of Surgery at Johns Hopkins in 1994 and subsequently earned a Sc.M. in clinical investigation at the Johns Hopkins Bloomberg School of Public Health. She has particular interest in melanoma at extremes of age, and in the factors associated with variance in melanoma care. Dr. Lange has published the largest study of melanoma in children, adolescents and young adults. She recognizes that melanoma in the older patient is a growing epidemic and has investigated the socioeconomic, demographic and healthcare factors that influence the treatment of melanoma in older persons. Dr. Lange is a member of the melanoma panel of the National Comprehensive Cancer Network, a group that annually evaluates and revises national treatment guidelines for melanoma. In 2015, she was inducted for her work into the Miller-Coulson Academy of Clinical Excellence, which recognizes outstanding clinicians at Johns Hopkins based on a number of factors, including communication and interpersonal skills, professionalism and humanism, a scholarly approach to clinical practice, and a passion for patient care. Dr. Lange is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Lymphadenectomy.

Dr. Sewon Kang is the Noxell Professor and Chairman of the Department of Dermatology at the Johns Hopkins University School of Medicine and the Dermatologist-in-Chief of Johns Hopkins Hospital. He is also founder and co-Director of the Cutaneous Translational Research Program (CTReP) at Hopkins. A recipient of the Dermatology Foundation's Career Development Award, he has received other research awards and grants from the American Dermatological Association, the National Psoriasis Foundation and the National Institutes of Health (Roadmap T32, K24, and R01). His research focus has been in the areas of skin pharmacology and photomedicine. He is the Past President of the Photomedicine Society, and the American Acne and Rosacea Society. Dr. Kang is or has been on the Board of Directors of multiple organizations including, the Society for Investigative Dermatology, the Association of Professors of Dermatology, the Dermatology Foundation, and the Skin of Color Society. An author on over 240 publications and book chapters, Dr. Kang is also the Editor-in-Chief of the 9th edition of the Fitzpatrick's Dermatology textbook. He is an inventor/co-inventor of 17 patents and has given over 300 presentations globally. A graduate with honors from Williams College and the University of Michigan, Dr. Kang completed dermatology residency and fellowship at the Harvard Medical School/Massachusetts General Hospital. He sees patients exclusively at the Johns Hopkins Hospital, and his areas of clinical expertise include photomedicine, skin cancer (melanoma), skin aging, and dermatology for ethnic skin. Dr. Kang is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Acne, Prurigo Nodularis, and Rosacea.

Maie John is an Otolaryngologist in Baltimore, Maryland. Dr. John is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Melanoma, Glossectomy, and Gastrostomy.

Dr. Jihad Mohamad Alhariri is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include dermatology and medical dermatology. Dr. Alhariri received his undergraduate degree from the American University of Beirut. He earned his M.D. from the American University of Beirut and his M.P.H. from the Johns Hopkins University School of Public Health. He completed a residency in internal medicine at Good Samaritan Hospital of Maryland and a residency in dermatology at Johns Hopkins. Dr. Alhariri is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Hidradenitis Suppurativa, Giant Congenital Melanocytic Nevus, and Giant Congenital Nevus.

Edward Mccarron is a General Surgeon and a Surgical Oncologist in Glen Burnie, Maryland. Dr. Mccarron is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Familial Pancreatic Cancer, Ogilvie Syndrome, Hernia Surgery, and Pancreatectomy. Dr. Mccarron is currently accepting new patients.

Maral Skelsey is a Dermatologist in Chevy Chase, Maryland. Dr. Skelsey is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Actinic Keratosis, Melanoma, Warts, and Seborrheic Keratosis.

Joseph Bennett is a General Surgeon and a Surgical Oncologist in Randallstown, Maryland. Dr. Bennett is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Pancreatic Adenoma, Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatectomy, and Small Bowel Resection. Dr. Bennett is currently accepting new patients.

Andrew Marek is a Dermatologist in Timonium, Maryland. Dr. Marek is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Trichoepithelioma, Multiple Familial Trichoepithelioma, and Syringoma. Dr. Marek is currently accepting new patients.

Tamy Buckel is a Dermatologist in Cambridge, Maryland. Dr. Buckel is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Actinic Keratosis, Warts, and Seborrheic Keratosis. Dr. Buckel is currently accepting new patients.

Dennis Kurgansky is a Dermatologist in Bel Air, Maryland. Dr. Kurgansky is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Giant Congenital Melanocytic Nevus, Familial Atypical Multiple Mole Melanoma Syndrome, Giant Congenital Nevus, and Melanoma. Dr. Kurgansky is currently accepting new patients.

Dr. Kleinberg specializes in the radiation treatments, including stereotactic radiosurgery, of brain and spinal tumors. Areas of research include both tumors arising in the central nervous system and tumors metastasizing from other locations. He also specializes in the treatment of esophageal tumors and has led national clinical trials in both therapy of brain tumors as well as esophageal cancer. Dr. Kleinberg has been recently named in the US News and World Report list of top 1% of doctors in his specialty. He is the co-chair of the Eastern Cooperative Oncology Group Brain Tumor Working Group, Vice-Chair of the NCI Cooperative Group Steering Committee for Esophageal and Gastric Tumors, and is a member of the NCI Cooperative Group Steering Committee for Gastrointestinal Tumors. He is also on the American College of Radiation Oncology Neurologic Cancer Practice Accreditation Team. Make A Gift. Dr. Kleinberg is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Hepato-Pancreato-Biliary Surgery, and Gamma Knife Radiosurgery.